

Organic & Biomolecular Chemistry

Accepted Manuscript



This article can be cited before page numbers have been issued, to do this please use: S. C. Pan, C. Gharui and S. Singh, *Org. Biomol. Chem.*, 2017, DOI: 10.1039/C7OB01766A.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [author guidelines](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the ethical guidelines, outlined in our [author and reviewer resource centre](#), still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.



Journal Name

COMMUNICATION

Received 00th January 20xx,
Accepted 00th January 20xx
DOI: 10.1039/x0xx00000x

www.rsc.org/

Chiral Phosphoric Acid Catalyzed Enantioselective Annulation of Acyclic Enecarbamates to In Situ-Generated *ortho*-Quinone Methides


Chandan Gharui, Shreya Singh and Subhas Chandra Pan*

The first organocatalytic asymmetric reaction of acyclic enecarbamates with *o*-quinone methides is disclosed. BINOL-based phosphoric acid catalysts were found to be suitable for the annulation reaction. With 10 mol% of TRIP catalyst, high yields as well as excellent diastereo- and enantioselectivities are achieved for a variety of 2,3,4-trisubstituted chroman products.


Over the years, *o*-quinone methides have been established as important synthetic intermediates in organic synthesis and material chemistry and also in biological processes.¹ The interesting structural figure and inherent reactivity with highly electrophilic character have led to the development of a variety of reactions namely Michael additions, 6π electrocyclizations and [4 + 2] cycloadditions. Despite long history of *o*-quinone methides, the catalytic asymmetric versions have only been realized in recent years possibly due to transient nature of *o*-quinone methides.² The initial important contributions have been documented by the groups of Sigman,³ Lectka,⁴ Schaus,⁵ Ye⁶ and Scheidt⁷ respectively on enantioselective palladium-, cinchona alkaloid-, BINOL-, and NHC catalysis with *o*-quinone methides. Later on, the groups of Bach,⁸ Rueping,⁹ Schneider¹⁰, Sun¹¹ and others¹² have demonstrated the chiral Brønsted acid catalyzed generation of *o*-quinone methides from *o*-hydroxybenzyl alcohols/*o*-hydroxy styrenes and applied in a variety of nucleophilic additions and cyclization reactions. In a parallel way, few reports on bifunctional tertiary amine-thiourea/squaramide as well as metal catalyzed employment of *in situ* generated *o*-quinone methides have been disclosed.^{13,14}

Densely functionalized chromans are important structural motifs that are present in many natural products and bioactive agents.¹⁵ Though a range of organocatalytic asymmetric approaches have been documented in literature,^{16,17} only two reports employing *o*-quinone methides are known as disclosed by Rueping^{9a} and Shi^{12b} for the synthesis of 2,4-disubstituted chromans using styrenes and vinyl indoles respectively.

Previous work: Cyclic enecarbamate



This work: Acyclic enecarbamate



Scheme 1 Enantioselective annulation of Enecarbamates with *in situ* Generated *o*-Quinone Methides.

Enamides and enecarbamates are also potential reactive nucleophiles that have been utilized in a wide range of C-C bond formation reactions.¹⁸ Schneider *et al.* has elegantly employed cyclic enamides with *in situ* generated *o*-quinone methides for the asymmetric synthesis of xanthene based heterocycles.^{10c-d} Though one example of reaction of cyclic enecarbamate has been demonstrated by Schneider and co-workers,^{10c} to the best of our knowledge acyclic enecarbamates have not been studied. Realizing the importance of highly substituted diverse chromans in natural products and for other studies, we embarked in the Brønsted acid catalyzed reactions of acyclic enecarbamates and *o*-quinone methides.


We first attempted the reaction between *o*-hydroxybenzyl alcohol **1a** and enecarbamate **2a** using BINOL-phosphoric acid **I** in toluene at room temperature (Table 1, entry 1). Though the reaction led to the formation of chroman mixtures **3a/3a'** in high yield but the enantiomeric excess was low. The relative structures of **3a** and **3a'** were solved by 2D NMR experiments. Then we planned to screen 3,3'-substituted BINOL-phosphoric acids and the results are pleasing. For example, catalyst **II** and **III** having 1-naphthyl and 2-naphthyl substitutions provided the products **3a/3a'** in good enantioselectivities but the diastereoselectivity was not improved. Sterically demanding catalyst **IV** having bis *meta*-CF₃ groups on the 3,3'-phenyl

Department of Chemistry, Indian Institute of Technology Guwahati, 781039, India. E-mail: span@iitg.ernet.in; Tel: +91-361-258-3304; Fax: +91-361-258-2349.

*Electronic Supplementary Information (ESI) available: Experimental details, characterization and analytical data. See DOI: 10.1039/x0xx00000x

COMMUNICATION

groups could not change the outcome of the reaction. An improvement in enantioselectivity was observed with catalyst **V** having 9-anthryl groups on the 3,3'-positions. Interestingly, more sterically demanding catalyst **VI** having 2,4,6-triisopropylated 3,3'-phenyl groups delivered the products in higher enantioselectivities and with higher diastereoselectivities (entry 6). The major diastereomer **3a** was obtained in 90% ee. The enantioselectivity did not improve after lowering the temperature. Other solvents were also screened but toluene was found to be the best solvent (see supporting information for details).


Table 1 Catalyst Screening and Optimization of Reaction Condition


R = H (I)
 R = 1-Naphthyl (II)
 R = 2-Naphthyl (III)
 R = 3,5-(CF₃)₂C₆H₃ (IV)
 R = 9-Anthryl (V)
 R = 2,4,6-(iPr)₃C₆H₃ (VI)

Entry ^a	Catalyst	Yield ^b	dr (3a/3a') ^c	ee (3a/3a') ^d
1	I	77	1:2	20/14
2	II	60	1:1.4	78/72
3	III	62	1:1	60/80
4	IV	65	1:1	54/70
5	V	71	1:2	88/74
6	VI	81	5.6:1	90/82

^aReaction condition: 0.04 mmol of **1a** and 0.06 mmol of **2a** in 0.2 mL toluene using 10 mol% catalyst at room temperature for 3 days. ^bIsolated yield after silica gel column chromatography. ^cDetermined by ¹H NMR. ^dDetermined by HPLC using stationary phase chiral column.

After the optimized conditions got established, the scope of the reaction was studied. Initially a variety of enecarbamates **2** having different substitutions on the aryl group of the olefin was examined (Table 2). Delightfully, the reactions proceeded well in all cases and typically completed within 3-4 days at room temperature. At the beginning, different *para*-substitutions were screened and high yields as well as excellent enantioselectivities were achieved for the products **3a-3g** (Table 2, entries 1-7). To our delight, products **3e-3g** having 4-halo substitutions were obtained in acceptable yields and with high diastereo- and enantioselectivities (entries 5-7). Then different *meta*- and *ortho*-substitutions were studied and here also the products were attained in high yields as well as with high enantioselectivities (entries 8-14). Interestingly, here the products with halo functionalities **3l-3n** were isolated almost as single diastereomers (entries 12-14). A disubstituted enecarbamate also withstood the reaction condition and delivered the major product **3o** in 92% ee (entry 15).


Table 2 Scope of N-Cbz Enecarbamates


Entry ^a	Ar	3	Yield ^b	dr ^c	ee ^d
1	Ph	3a	81	5.6:1	90
2	4-MeC ₆ H ₄	3b	84	5:1	92
3	4- ⁱ PrC ₆ H ₄	3c	85	8.3:1	88
4	4- ^t BuC ₆ H ₄	3d	87	9.1:1	88
5	4-FC ₆ H ₄	3e	74	>20:1	84
6	4-ClC ₆ H ₄	3f	48	8.3:1	92
7	4-BrC ₆ H ₄	3g	53	9:1	94
8	3-MeC ₆ H ₄	3h	70	10:1	92
9	3-ClC ₆ H ₄	3i	48	5:1	94
10	3-BrC ₆ H ₄	3j	80	20:1	94
11	2-MeC ₆ H ₄	3k	72	4.2:1	88
12	2-FC ₆ H ₄	3l	83	>20:1	94
13	2-ClC ₆ H ₄	3m	88	>20:1	94
14	2-BrC ₆ H ₄	3n	89	>20:1	94
15	2,4-Me ₂ C ₆ H ₃	3o	63	4.3:1	92


^aReactions were carried out with catalyst **VI** in toluene at room temperature for 3-4 days. ^bIsolated yield after silica gel column chromatography. ^cDetermined by ¹H NMR. ^dDetermined by HPLC and of the major diastereomer.

The next phase of experiments involved variation the carbamate moiety and gratifyingly, the fate of the reaction was unaffected (Table 3). Good to high yields as well as high enantioselectivities were maintained with *S*-benzyl carbamothioate **2p** and other enecarbamates **2q-2s** albeit slight less diastereoselectivity was obtained for product **3q** (Table 3).

The generality of the reaction was further shown by employing a range of *o*-hydroxybenzyl alcohols (Table 4). Gratifyingly, a range of *o*-hydroxybenzyl alcohols having variations both on the quinone methide fragment and β -aryl substituent could be engaged in the reaction and good results were produced. Initially different halo substitutions on the quinone methide component was screened and high enantioselectivities were attained for products **3t-3v** which can be further functionalized *via* metal catalyzed cross-coupling reactions. To our delight, excellent diastereoselectivity was observed for product **3u**. However, the reactions were sluggish for products **3u** and **3v** and needed to run for 6 days at room temperature and at 50 °C for 3 days respectively. The enantioselectivity was also high when the β -aryl substituent was varied and acceptable yields were observed for products **3w** and **3x** (Table 4). Then we investigated reaction with different β -alkyl substituents and

Table 3 Scope of Other Enecarbamates^{a,b}

^aReaction was carried out with catalyst **VI** in toluene at room temperature for 3 days. ^bIsolated yield after silica gel column chromatography, diastereoselectivity was determined by ¹H NMR and enantioselectivity was determined by HPLC using stationary phase chiral column.


Table 4 Scope of *o*-Hydroxybenzyl Alcohols^{a,b}

^aReaction was carried out with catalyst **VI** in toluene at room temperature for 3 days. ^bIsolated yield after silica gel column chromatography, diastereoselectivity was determined by ¹H NMR and enantioselectivity was determined by HPLC using stationary phase chiral column. ^cReaction was run at room temperature for 6 days. ^dAt 50 °C for 3 days.

gratifyingly the reaction progressed well with alcohol **1g** having phenyl acetylene motif delivering product **3y** in 61% yield with 52% ee.

A plausible mechanism for the formation of chroman **3** has been depicted in Scheme 2. In the first step, protonation followed by dehydration of the *o*-hydroxybenzyl alcohol **1** catalyzed by phosphoric acid leads to the formation of *o*-quinone methide **A**. Then the bifunctional character of phosphoric acid plays a role in bringing *o*-quinone methide **A** and enecarbamate **2** together. Presumably, the catalyst is hydrogen-bonded to the oxygen atom of the *o*-quinone methide **A** through its acidic group O-H and simultaneously connected to the enecarbamate N-H moiety through an additional hydrogen bond from the basic phosphoryl oxygen atom (Scheme 2).^{10c}

Also, the enecarbamate **2** adjusts in *endo* fashion and consequently the reaction occurs in a concerted pathway that explains the relative *trans*-structure of **3** (see supporting information for additional experiments). The absolute structure of compound **3q** was determined to be (2*S*,3*R*,4*R*) by Mosher amide method¹⁹ and the other products are assumed to have same absolute configuration (see supporting information for details).

**Scheme 2** Proposed Mechanism

In summary, this work represents a fascinating catalytic asymmetric reaction between *o*-quinone methides and acyclic enecarbamates. The reaction is catalyzed by commercially available chiral phosphoric acid *TRIP*. The synthesis of chroman products having two aryl substitutions is difficult and thus our method is significant which allow for the synthesis of chromans having three stereogenic centres and could be applied in natural product synthesis.

Acknowledgements

This work is supported by DST-MPI partner programme. We thank CIF, Indian Institute of Technology Guwahati for the instrumental facility. We are also thankful to Prof. Benjamin List for the kind donation of *TRIP* catalyst.

Notes and references

- 1 For selected recent reviews about *o*-QMs, see: (a) *Quinone Methides* (Ed.: S. E. Rokita), Wiley: Hoboken, 2009; (b) T. P. Pathak and M. S. Sigman, *J. Org. Chem.*, 2011, **76**, 9210; (c) N. J. Willis and C. D. Bray, *Chem. Eur. J.*, 2012, **18**, 9160; (d) W. J. Bai, J. G. David, Z. G. Feng, M. G. Weaver, K. L. Wu and T. R. Pettus, *Acc. Chem. Res.*, 2014, **47**, 3655; (e) L. Caruana, M. Fochi and L. Bernardi, *Molecules*, 2015, **20**, 11733.
- 2 For reviews, see: (a) Z. Wang and J. Sun, *Synthesis*, 2015, **47**, 3629; (b) A. A. Jaworski and A. A. Scheidt, *J. Org. Chem.*, 2016, **81**, 10145.
- 3 (a) Y. Zhang and M. S. Sigman, *J. Am. Chem. Soc.*, 2007, **129**, 3076; (b) K. H. Jensen, T. P. Pathak, Y. Zhang and M. S. Sigman, *J. Am. Chem. Soc.*, 2009, **131**, 17074; (c) T. P. Pathak, K. M. Gligorich, B. E. Welm and M. S. Sigman, *J. Am. Chem. Soc.*, 2010, **132**, 7870; (d) K. H. Jensen, J. D. Webb and M. S. Sigman, *J. Am. Chem. Soc.*, 2010, **132**, 17471; (e) R. Jana, T. P. Pathak, K. H. Jensen and M. S. Sigman, *Org. Lett.*, 2012, **14**, 4074.
- 4 E. Alden-Danforth, M. T. Scerba and T. Lectka, *Org. Lett.*, 2008, **10**, 4951.
- 5 Y. Luan and S. E. Schaus, *J. Am. Chem. Soc.*, 2012, **134**, 19965.
- 6 (a) H. Lv, L. You and S. Ye, *Adv. Synth. Catal.*, 2009, **351**, 2822; (b) H. Lv, W. Q. Jia, L. H. Sun and S. Ye, *Angew. Chem. Int. Ed.*, 2013, **125**, 8769.
- 7 (a) A. E. Mattson and K. A. Scheidt, *J. Am. Chem. Soc.*, 2007, **129**, 4508; (b) J. Izquierdo, A. Orue and K. A. Scheidt, *J. Am. Chem. Soc.*, 2013, **135**, 10634; (c) A. Lee, A. Younai, C. K. Price, J. Izquierdo, R. K. Mishra and K. A. Scheidt, *J. Am. Chem. Soc.*, 2014, **136**, 10589.
- 8 D. Wilcke, E. Herdtweck and T. Bach, *Synlett*, 2011, **22**, 1235.
- 9 (a) C.-C. Hsiao, H.-H. Liao and M. Rueping, *Angew. Chem. Int. Ed.*, 2014, **53**, 13258; (b) C.-C. Hsiao, S. Raja, H.-H. Liao, I. Atodiresei and M. Rueping, *Angew. Chem. Int. Ed.*, 2015, **54**, 1910.
- 10 (a) O. El-Sepelgy, S. Haseloff, S. K. Alamsetti and C. Schneider, *Angew. Chem. Int. Ed.*, 2014, **53**, 7923; (b) S. Saha, S. K. Alamsetti and C. Schneider, *Chem. Commun.*, 2015, **51**, 1461; (c) S. Saha and C. Schneider, *Chem. –Eur. J.*, 2015, **21**, 2348; (d) S. Saha and C. Schneider, *Org. Lett.*, 2015, **17**, 648; For a Rh/Brønsted acid catalysis, see: S. K. Alamsetti, M. Spanka and C. Schneider, *Angew. Chem. Int. Ed.*, 2016, **55**, 2392.
- 11 (a) W. Zhao, Z. Wang, B. Chu and J. Sun, *Angew. Chem. Int. Ed.*, 2015, **54**, 1910; (b) Z. Wang, F. Ali, Z. Wang, W. Zhao, G. Zhu, Z. Lin and J. Sun, *J. Am. Chem. Soc.*, 2015, **137**, 383; (c) Z. Lai, Z. Wang and J. Sun, *Org. Lett.*, 2015, **17**, 6058; (d) Z. Lai and J. Sun, *Synlett*, 2016, **27**, 555.
- 12 (a) R.-Y. Zhu, C.-S. Wang, J. Zheng, F. Shi and S.-J. Tu, *J. Org. Chem.*, 2014, **79**, 9305; (b) J.-J. Zhao, S.-B. Sun, S.-H. He, Q. Wu and F. Shi, *Angew. Chem. Int. Ed.*, 2015, **54**, 5460; (c) Y.-C. Zhang, Q.-N. Zhu, X. Yang, L.-J. Zhou and F. J. Shi, *Org. Chem.*, 2016, **81**, 1681; (d) Q. Wu, C. Ma, X.-h. Du, Y. Chen, T.-z. Huang, X.-q. Shi, S.-j. Tu and P.-j. Cai, *Tetrahedron: Asymmetry*, 2016, **27**, 307; (e) M. Tang, J.-J. Zhao, Q. Wu, M. S. Tu, F. Shi, *Synthesis*, 2017, **49**, 2035; For *o*-QM intermediate in Prins reaction, see: (f) G. C. Tsui, L. Liu and B. List, *Angew. Chem. Int. Ed.*, 2015, **54**, 7703.
- 13 For selected examples, see: (a) W. Guo, B. Wu, X. Zhou, P. Chen, X. Wang, Y.-G. Zhou, Y. Liu and C. Li, *Angew. Chem. Int. Ed.*, 2015, **54**, 4522; (b) L. Carruna, M. Mondatori, V. Corti, S. Morales, A. Mazzanti, M. Fochi and L. Bernardi, *Chem. –Eur. J.*, 2015, **21**, 6037; (c) B. Wu, X. Gao, Z. Yan, W.-X. Huang and Y.-G. Zhou, *Tetrahedron Lett.*, 2015, **56**, 4334; (d) Y. Wang, C. Zhang, H. Wang, Y. Jiang, X. Du and D. Xu, *Adv. Synth. Catal.*, 2017, **359**, 791; (e) B. Wu, Z. Yu, X. Gao, Y. Lan and Y.-G. Zhou, *Angew. Chem. Int. Ed.*, 2017, **129**, 4064; For primary amine catalyzed addition to *o*-QMs, see: (f) Y. Zhu, L. Zhang and S. Luo, *J. Am. Chem. Soc.*, 2016, **138**, 3978; For a recent report using NHC, see: (g) Y. Wang, J. Pan, J. Dong, C. Yu, T. Li, X.-S. Wang, S. Shen and C. Yao, *J. Org. Chem.*, 2017, **82**, 1790.
- 14 For metal catalyzed reports, see: (a) H. Xu, Y. Liu, J. Guo, L. Lin, Y. Xu, X. Liu and X. Feng, *Chem. Commun.*, 2015, **51**, 3835; (b) Y. Huang and T. Hayashi, *J. Am. Chem. Soc.*, 2015, **137**, 7556; (c) M. Liang, S. Zhang, J. Jia, C.-H. Tung, J. Wang and Z. Xu, *Org. Lett.*, 2017, **19**, 2526.
- 15 For selected examples, see: (a) S. R. Trenor, A. R. Shultz, B. J. Love and T. E. Long, *Chem. Rev.*, 2004, **104**, 3059; (b) M. C. Breschi, V. Calderone, A. Martelli, F. Minutolo, S. Rapposelli, L. Testai, F. Tonelli and A. Balsamo, *J. Med. Chem.*, 2006, **49**, 7600; (c) S. Khelili, X. Florence, M. Bouhadja, S. Abdelaziz, N. Mechouch, Y. Mohamed, P. D. de Tullio, P. Lebrun and B. Pirotte, *Bioorg. Med. Chem.*, 2008, **16**, 6124; (d) A. Coi, A. M. Bianucci, V. Calderone, L. Tstai, M. Digiacomo, S. Rapposelli and A. Balsamo, *Bioorg. Med. Chem.*, 2009, **17**, 5565.
- 16 For selected recent examples, see: (a) H. Sunden, I. Ibrahim, G.-L. Zhao, L. Eriksson and A. Córdova, *Chem. –Eur. J.*, 2007, **13**, 574; (b) L. Zu, S. Zhang, H. Xie and W. Wang, *Org. Lett.*, 2009, **11**, 1627; (c) B.-C. Hong, P. Kotame, C.-W. Tsai and J.-H. Liao, *Org. Lett.*, 2010, **12**, 776; (d) X.-F. Wang, Q.-L. Hua, Y. Cheng, A.-L. An, Q.-Q. Yang, J.-R. Chen and W.-J. Xiao, *Angew. Chem. Int. Ed.*, 2010, **49**, 8379; (e) X.-F. Wang, J. An, X.-X. Zhang, F. Tan, J.-R. Chen and W.-J. Xiao, *Org. Lett.*, 2011, **13**, 808; (f) D. B. Ramachary, M. S. Shiva Prasad and R. Madhavachary, *Org. Biomol. Chem.*, 2011, **9**, 2715; (g) Z.-X. Jia, Y.-C. Luo, X.-N. Cheng, P.-F. Xu and Y.-C. J. Gu, *Org. Chem.*, 2013, **78**, 6488; (h) P. H. Poulsen, K. S. Feu, B. M. Paz, F. Jensen and K. A. Jørgensen, *Angew. Chem. Int. Ed.*, 2015, **54**, 8203; (i) P. Saha, A. Biswas, N. Molletti and V. A. Singh, *J. Org. Chem.*, 2015, **80**, 11115; (j) Y. Zhu, X. Li, Q. Chen, J. Su, F. Jia, S. Qiu, M. Ma, Q. Sun, W. Yan, K. Wang and R. Wang, *Org. Lett.*, 2015, **17**, 3826.
- 17 For selected reviews on the synthesis of chroman derivatives using organocatalysts, see: (a) M. G. Núñez, P. García, R. F. Moro and D. Díez, *Tetrahedron*, 2010, **66**, 2089; (b) C. Bhanja, S. Jena, S. Nayak and S. Mohapatra, *Beilstein J. Org. Chem.*, 2012, **8**, 1668; (c) C. F. Nising and S. Brase, *Chem. Soc. Rev.*, 2012, **41**, 988.
- 18 For a review, see: K. Gopalaiah and H. B. Kagan, *Chem. Rev.*, 2011, **111**, 4599.
- 19 For a review, see: J. M. Seco, E. Quinoa and R. Riguera, *Chem. Rev.*, 2004, **104**, 17.